Recommendations for Use of Free Light Chain Assay in Monoclonal Gammopathies

Open access

Recommendations for Use of Free Light Chain Assay in Monoclonal Gammopathies

The serum immunoglobulin free light chain assay measures levels of free κ and λ immunoglobulin light chains. There are three major indications for the free light chain assay in the evaluation and management of multiple myeloma and related plasma cell disorders. In the context of screening, the serum free light chain assay in combination with serum protein electrophoresis and immunofixation yields high sensitivity, and negates the need for 24-hour urine studies for diagnoses other than light chain amyloidosis. Second, the baseline free light chains measurement is of major prognostic value in virtually every plasma cell disorder. Third, the free light chain assay allows for quantitative monitoring of patients with oligosecretory plasma cell disorders, including AL, oligosecretory myeloma, and nearly twothirds of patients who had previously been deemed to have non-secretory myeloma. In AL patients, serial free light chains measurements outperform protein electrophoresis and immunofixation. In oligosecretory myeloma patients, although not formally validated, serial free light chains measurements reduce the need for frequent bone marrow biopsies. In contrast, there are no data to support using free light chain assay in place of 24-hour urine electrophoresis for monitoring or for serial measurements in plasma cell disorders with measurable disease by serum or urine electrophoresis.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • Bradwell AR Carr-Smith HD Mead GP Tang LX Showell PJ Drayson MT et al. Highly sensitive automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 2001; 47: 673-80.

  • Bradwell AR. Serum free light chain measurements move to center stage. Clin Chem 2005; 51: 805-7.

  • Bradwell AR Carr-Smith HD Mead GP Harvey TC Drayson MT. Serum test for assessment of patients with Bence Jones myeloma. Lancet 2003; 361: 489-91.

  • Katzmann JA Clark RJ Abraham RS Bryant S Lymp JF Bradwell AR et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem 2002; 48: 1437-44.

  • Nakano T Nagata A. ELISAs for free light chains of human immunoglobulins using monoclonal antibodies: comparison of their specificity with available polyclonal antibodies. J Immunol Methods 2003; 275: 9-17.

  • Tate JR Mollee P Dimeski G Carter AC Gill D. Analytical performance of serum free lightchain assay during monitoring of patients with monoclonal lightchain diseases. Clin Chim Acta 2007; 376: 30-6.

  • Daval S Tridon A Mazeron N Ristori JM Evrard B. Risk of antigen excess in serum free light chain measurements. Clin Chem 2007; 53: 1985-6.

  • Katzmann JA Dispenzieri A Kyle RA Snyder MR Plevak MF Larson DR et al. Elimination of the need for urine studies in the screening algorithm for monoclonal gammopathies by using serum immunofixation and free light chain assays. Mayo Clin Proc 2006; 81: 1575-8.

  • Beetham R Wassell J Wallage MJ Whiteway AJ James JA. Can serum free light chains replace urine electrophoresis in the detection of monoclonal gammopathies? Ann Clin Biochem 2007; 44: 516-22.

  • Katzmann JA Abraham RS Dispenzieri A Lust JA Kyle RA. Diagnostic Performance of Quantitative {kappa} and {lambda} Free Light Chain Assays in Clinical Practice. Clin Chem 2005; 51: 878-81.

  • Nowrousian MR Brandhorst D Sammet C Kellert M Daniels R Schuett P et al. Serum free light chain analysis and urine immunofixation electrophoresis in patients with multiple myeloma. Clin Cancer Res 2005; 11: 8706-14.

  • Hill PG Forsyth JM Rai B Mayne S. Serum free light chains: an alternative to the urine Bence Jones proteins screening test for monoclonal gammopathies. Clin Chem 2006; 52: 1743-8.

  • Abadie JM Bankson DD. Assessment of serum free light chain assays for plasma cell disorder screening in a Veterans Affairs population. Ann Clin Lab Sci 2006; 36: 157-62.

  • Kang SY Suh JT Lee HJ Yoon HJ Lee WI. Clinical usefulness of free light chain concentration as a tumor marker in multiple myeloma. Ann Hematol 2005; 84: 588-93.

  • Bakshi NA Gulbranson R Garstka D Bradwell AR Keren DF. Serum free light chain (FLC) measurement can aid capillary zone electrophoresis in detecting subtle FLC-producing M proteins. Am J Clin Pathol 2005; 124: 214-8.

  • Marien G Oris E Bradwell AR Blanckaert N Bossuyt X. Detection of monoclonal proteins in sera by capillary zone electrophoresis and free light chain measurements. Clin Chem 2002; 48: 1600-1.

  • Kumar S Fonseca R Dispenzieri A Katzmann JA Kyle RA Clark R et al. High Incidence of IgH Translocations in Monoclonal Gammopathies with Abnormal Free Light Chain Levels. ASH Annual Meeting Abstracts 2006; 108: 3514.

  • Dispenzieri A Lacy MQ Katzmann JA Rajkumar SV Abraham RS Hayman SR et al. Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2006; 107: 3378-83.

  • Bradwell AR. Serum free light chain analysis 3rd ed 2005: 13-21. The Binding Site Ltd. Birmingham UK.

  • Keren DF. Procedures for the evaluation of monoclonal immunoglobulins. Arch Pathol Lab Med 1999; 123: 126-32.

  • Waller KV Ward KM Mahan JD Wismatt DK. Current concepts of proteinuria. Clin Chem 1989; 35: 755-65.

  • Van Rhee F Bolejack V Hollmig K Pineda-Roman M Anaissie E Epstein J et al. High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood 2007; 110: 827-32.

  • Rajkumar SV Kyle RA Therneau TM Melton LJ 3rd Bradwell AR Clark RJ et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 2005; 106: 812-7.

  • Kyle RA Remstein E Therneau TM Dispenzieri A Kurtin PJ Hodnefield J et al. Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma. New England Journal of Medicine 2007; 356: 2582-90.

  • Giot J-F. Agarose gel electrophoresisi - aplications in Clinical Chemistry. Journal of Medical Biochemistry 2010; 29: 9-14.

  • Mischak H Schiffer E Zübig P Dakna M Metzger. J. Urinary proteome analysis using capillary electrophoesis coupled to mass spectrometry: A powerful tool in clinical diagnosis prognosis and therapy evaluation. Journal of Medical Biochemistry 2009; 28: 223-234.

  • Dingli D Kyle RA Rajkumar SV Nowakowski GS Larson DR Bida JP et al. Immunoglobulin free light chains and solitary plasmacytoma of bone. Blood 2006; 108: 1979-83.

  • Dispenzieri A Zhang L Katzmann JA Snyder M Blood E Degoey R et al. Appraisal of immunoglobulin free light chain as a marker of response. Blood 2008; 111: 4908-15.

  • Snozek CL Katzmann JA Kyle RA Dispenzieri A Larson DR Therneau TM et al. Prognostic value of the serum free light chain ratio in patients with newly diagnosed myeloma and proposed incorporation into the International Staging System. Leukemia 2008; 22: 1933-37.

  • Greipp PR San Miguel J Durie BG Crowley JJ Barlogie B Blade J et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412-20.

Impact Factor

IMPACT FACTOR 2018: 2.000
5-year IMPACT FACTOR: 1.075

CiteScore 2018: 1.47

SCImago Journal Rank (SJR) 2018: 0.523
Source Normalized Impact per Paper (SNIP) 2018: 0.581

Cited By
Gesamte Zeit Letztes Jahr Letzte 30 Tage
Abstract Views 0 0 0
Full Text Views 206 137 0
PDF Downloads 76 60 1